[PharmaEssentia] Notice of Completion of Patient Enrollment for Phase 3 Trial

1. Drug Name: Ropeginterferon alfa-2b (P1101) 2. Indication: Pre-fibrotic/Early Primary Myelofibrosis and low/intermediate-1 risk Overt Primary Myelofibrosis. 3. Progress: Completed enrollment of 160 subjects in the Phase 3 clinical trial (HOPE-PMF). 4. Next Step: Continuing the Phase 3 trial, expected completion in 2027. 5. Context: Myelofibrosis is a type of myeloproliferative neoplasm. Existing treatments include JAK2 inhibitors, and this trial explores a new treatment option.